Evidence map›Paper›PMID 42176118›Full record

ArticleDermatology and therapy2026

Criteria for Hidradenitis Suppurativa Competence Centers.

Angelo V Marzano, Falk G Bechara, Vivian Y Shi, Antonio Martorell, Jennifer L Hsiao, Hessel H Van der Zee, Axel P Villani, Afsaneh Alavi, John R Ingram, Christopher J Sayed and 14 more

Abstract read
In one paragraph

Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Angelo V MarzanoDermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Falk G BecharaEuropean Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
Vivian Y ShiDepartment of Dermatology, University of Washington, Seattle, WA, USA.
Antonio MartorellEuropean Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
Jennifer L HsiaoDepartment of Dermatology, University of Southern California, Los Angeles, CA, USA.
Hessel H Van der ZeeEuropean Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
Axel P VillaniEuropean Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
Afsaneh AlaviEuropean Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
John R IngramEuropean Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
Christopher J SayedEuropean Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
Thrasyvoulos TzellosEuropean Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
Nisha Suyien ChandranDivision of Dermatology, Department of Medicine, National University Hospital, Singapore, Singapore.
Qiang JuEuropean Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
Ichiro KurokawaEuropean Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
John W FrewUniversity of New South Wales, Sydney, NSW, Australia.
Wayne P F GulliverEuropean Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
Maria Cecilia Rivitti-MachadoEuropean Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
Ximena WortsmanEuropean Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
Barry M McGrathEuropean Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
Giuseppina PintoriDirettore Generale Passione People Aps, Ciampino, Rome, Italy.
Valeria JordanNovartis Pharma AG, Basel, Switzerland.
Nicolas ThomasNovartis Pharma AG, Basel, Switzerland.
Ivette AlarconNovartis Pharma AG, Basel, Switzerland.
Christos C ZouboulisEuropean Hidradenitis Suppurativa Foundation e.V., Dessau, Germany. christos.zouboulis@mhb-fontane.de.ORCID http://orcid.org/0000-0003-1646-2608

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHidradenitis suppurativa (HS) is a chronic, systemic, immune-mediated disease requiring multimodal care, which is crucial for raising awareness and advancing treatment. This project aimed to establish consensus among HS experts to define HS Competence Centers (HSCC) criteria using the Delphi consensus method.

methodsOverall, 22 global HS experts (3 patient representatives and 19 healthcare professionals [HCPs]) from 16 countries across 5 continents were invited to participate. Subsequently, a three-step Delphi polling was conducted among the HS experts from 20 May 2024 to 8 July 2024. A 50% agreement was required to reach consensus. Consensus levels included strong consensus (≥ 95%), consensus (≥ 75%), majority agreement (≥ 50%) and no majority agreement (< 50%).

resultsIn the prepolling step, 22 participants proposed 26 criteria. In step 1, 23 criteria were selected, of which 6 (23.1%) reached strong consensus, 11 (42.3%) reached consensus, and 6 (23.1%) majority agreement. The remaining 3 (11.5%) criteria proposed were rejected. In step 2, 13 of the 23 criteria (56.5%) were proposed for wording modifications. Of these, four (30.8%) retained initial wording and nine (69.2%) were modified. In step 3, 21 of the 23 criteria were identified as very important (91.3%), while 2 (8.7%) were considered less important. Among the 21 very important criteria, 2 (9.5%) reached strong consensus, i.e., essential, 12 (57.1%) reached consensus, and 7 (33.4%) had majority agreement. Overall, a set of 23 criteria (2 essential, 12 required-1st grade, 7 required-2nd grade, and 2 potential) was recommended to establish HSCC.

conclusionsThis article reveals a consensus among an international group of HCPs and patients on a series of evidence-based criteria for HSCC. Standardized care, a hub and spoke model, multidisciplinary teams, specialized treatments, well-defined protocols, patient education, medical training, and robust referral systems were identified as essential/very important criteria for HSCC.

Indexed as

Competence centersConsensusDelphiHidradenitis suppurativaMultidisciplinaryPatient-centered care

Identifiers

PMID42176118
PMCPMC13280284

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.